Long-term Benefit of MPA in Liver Transplantation

MPA drugs are antiproliferative immunosuppressants and are widely used in solid organ transplantation. MPA drugs do not affect the recipient's kidney function and do not cause metabolic abnormalities and other problems. Intestinal solvent-based MPA drugs are widely used in clinical practice by improving the dosage form, reducing the irritation of MPA to the mucosa of the digestive tract, improving the tolerability of patients and maintaining a sufficient amount of MPA. However, data on the use/long-term use of intestinal solvent-based MPAs in liver transplant recipients are lacking. The study aims to evaluate the long-term benefits of enteric-coated mycophenolic acid in liver transplant recipients.

Inclusion Criteria:Patients who underwent their first liver transplantation between January 1, 2016 and February 28, 2021;Recipient's survival time≥ 1 year;Age 18~65 years old;Patients with complete data and no loss to follow-up.Exclusion Criteria:use of other types of anti-metabolic immunosuppressants;Second liver transplantation for various reasons within 1 year after the first transplantation;Patients with serious underlying diseases, including heart disease, infection and renal insufficiency, combined with other malignant tumors.